Thioaptamers targeting dengue virus type-2 envelope protein domain III

Sai Hari A Gandham; David E Volk; Ganesh L R Lokesh; Muniasamy Neerathilingam; David G Gorenstein

doi:10.1016/j.bbrc.2014.09.053

Thioaptamers targeting dengue virus type-2 envelope protein domain III

Biochem Biophys Res Commun. 2014 Oct 24;453(3):309-15. doi: 10.1016/j.bbrc.2014.09.053. Epub 2014 Sep 26.

Authors

Sai Hari A Gandham¹, David E Volk², Ganesh L R Lokesh², Muniasamy Neerathilingam¹, David G Gorenstein³

Affiliations

¹ Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
² Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Nanomedicine and Biomedical Engineering, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
³ Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Nanomedicine and Biomedical Engineering, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Electronic address: David.G.Gorenstein@uth.tmc.edu.

Abstract

Thioaptamers targeting the dengue-2 virus (DENV-2) envelope protein domain III (EDIII) were developed. EDIII, which contains epitopes for binding neutralizing antibodies, is the putative host-receptor binding domain and is thus an attractive target for development of vaccines, anti-viral therapeutic and diagnostic agents. Thioaptamer DENTA-1 bound to DENV-2 EDIII adjacent to a known neutralizing antibody binding site with a dissociation constant of 154nM.

Keywords: Anti-viral; Dengue virus; Diagnostic agent; Envelope protein; SELEX; Thioaptamer.

Published by Elsevier Inc.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing / immunology
Antiviral Agents / pharmacology*
Aptamers, Nucleotide / chemistry
Aptamers, Nucleotide / pharmacology*
Base Sequence
Dengue Virus / chemistry
Dengue Virus / drug effects*
Magnetic Resonance Spectroscopy
Viral Envelope Proteins / chemistry
Viral Envelope Proteins / drug effects*
Viral Envelope Proteins / immunology

Substances

Antibodies, Neutralizing
Antiviral Agents
Aptamers, Nucleotide
Viral Envelope Proteins

Abstract

Publication types

MeSH terms

Substances

Grants and funding